Why Isn’t Anyone Watching This Biotech Do Everything Right?

Here’s a test of whether your analyst does actual homework or just regurgitates press releases: ask them about Regeneron’s (REGN) development balance with Sanofi (SNY). I can almost guarantee the blank stares that usually follow.

That obscure line item buried in the 10-Q filing dropped $253 million last quarter to $1.2 billion, which means Regeneron’s profit share from their $4 billion blockbuster Dupixent keeps expanding.

I know your analyst missed it because Wall Street has been missing the built-in earnings accelerator because they’re too lazy to read past page ten of regulatory filings.

What this means is that while everyone’s obsessing over biosimilar competition eroding Eylea sales, they’re completely missing what’s actually happening beneath the surface. Regeneron just posted second-quarter revenue of $3.68 billion, beating consensus by nearly $400 million.

More importantly, they’re sitting on a pipeline that would make most Big Pharma executives weep with envy: 45 product candidates, 13 in Phase III trials.

Now, let’s go back and talk about Regeneron and Sanofi.

Dupixent, their collaboration with Sanofi, hit $4 billion in quarterly sales. Think about that number for a moment. This single drug generates revenue exceeding the entire market cap of many mid-tier pharmaceutical companies.

And it’s not slowing down – sales jumped 16% year-over-year, driven by recent FDA approvals for chronic spontaneous urticaria and bullous pemphigoid. The Street expected Dupixent to plateau. Instead, it’s accelerating.

That development balance I mentioned earlier? As it declines, Regeneron’s economics improve dramatically. That means every dollar reduction translates directly into higher profit margins from Dupixent sales.

It’s a built-in earnings accelerator that most analysts haven’t even noticed because they’re fixated on quarterly revenue beats rather than understanding the structural improvements happening in the business model.

Now let’s address the elephant everyone keeps pointing at: Eylea biosimilar competition. Yes, sales took a hit. Yes, Amgen (AMGN) and Roche (RHHBY) are gaining ground.

But something fascinating happened in the second quarter: Eylea sales actually increased 2.4% sequentially to $754 million. The bleeding has stopped.

Surprisingly, the market hasn’t noticed this, which is why Regeneron’s stock is stuck in accumulation between $550 and $605 while earnings keep climbing.

The real story, though, is Libtayo. This PD-1 inhibitor is carving out share in oncology against Merck’s (MRK) Keytruda and Bristol-Myers Squibb’s (BMY) Opdivo – drugs with massive head starts and marketing budgets that could fund small nations.

Libtayo posted $377 million in quarterly sales, up 32% sequentially. The EMPOWER-Lung 3 trial results published in September showed median overall survival of 21.1 months versus 12.9 months for chemotherapy alone in metastatic non-small cell lung cancer.

On top of these, Regeneron recently released Phase II data from their COURAGE study combining garetosmab and trevogrumab with Novo Nordisk’s (NVO) Wegovy.

Patients on the triple combination lost only 0.9 kilograms of lean mass compared to 3.3 kilograms on Wegovy alone, while achieving 11.8 kilograms of fat loss.

The obesity market is the pharmaceutical gold rush of this decade, and Regeneron just found a way to preserve muscle while enhancing fat reduction. The market yawned. I’m not yawning.

Meanwhile, management is executing a masterclass in capital allocation. They repurchased $1.08 billion in shares during the second quarter – up 16.5% year-over-year – while simultaneously investing over $7 billion in U.S. manufacturing expansion.

They’re building a state-of-the-art fill-finish facility in Rensselaer, New York, and partnering with Fujifilm (FUJIY) to diversify away from their troubled relationship with Catalent. These signals Regeneron’s move to prepare for massive volume growth while reducing dependency on external manufacturers who’ve had quality control issues.

The valuation makes this even more compelling. Regeneron’s trading at 14.6 times forward earnings, 18% below the sector median.

By 2029, assuming even modest pipeline success, that multiple drops to 9.7 times. That’s a 46% discount. You’re essentially getting a pharmaceutical company with blockbuster drugs, accelerating growth, and a pipeline worth tens of billions for the price of a mature industrial business.

Sure, the risks exist. Trump’s threatening tariffs on branded medications, though, Regeneron’s expanding U.S. manufacturing footprint largely insulates them. Itepekimab disappointed in COPD trials, but that’s one setback in a portfolio of dozens. The broader sector faces political headwinds, which is precisely why the buying opportunity exists.

Let’s be honest about what’s really happening here. You’ve got a company printing cash, beating earnings estimates, expanding margins, and trading at 14.6 times forward earnings while the sector median sits eighteen percent higher. The market is pricing in a catastrophe while management is aggressively buying back stock.

One of these parties has better information, and it’s not the analysts recycling the same biosimilar concerns they’ve been writing about for two years. Buy the dip.